Comparative studies of the enhancing effects of cyclodextrins on the solubility and oral bioavailability of tacrolimus in rats

Journal of Pharmaceutical Sciences

Volumn 90, Issue 6, 2001, Pages 690-701

  Arima, Hidetoshi ^a   Yunomae, Kiyokazu ^a   Miyake, Kouzou ^a   Irie, Tetsumi ^a   Hirayama, Fumitoshi ^a   Uekama, Kaneto ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Bioavailability; Complexation; Dimethyl cyclodextrin; Oral absorption; PROGRAF ; Tacrolimus

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; BETA CYCLODEXTRIN SULFOBUTYL ETHER; CYCLODEXTRIN DERIVATIVE; HEPTAKIS(2,6 O DIMETHYL) BETA CYCLODEXTRIN; TACROLIMUS;

ANIMAL EXPERIMENT; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG FORMULATION; DRUG SOLUBILITY; ENTHALPY; MALE; NONHUMAN; RAT;

EID: 0034988419     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.1025     Document Type: Article

References (36)

1. Novel immunosuppressive agent FK506: In vitro effects on the cloned T cell activation
2. Cyclosporin A, FK506 and rapamycin: Pharmacological probes of lymphocyte signal transduction
3. FK506 enters the clinic
4. Tacrolimus ointment for atopic dermatits
5. Successful treatment of resistant facial lesions of atopic dermatitis with 0.1% FK506 ointment
6. A short-term trial of tacrolimus ointment for atopic dermatitis
7. Clinical pharmacokinetics of tacrolimus
8. Absorption, distribution, metabolism and excretion of tacrolimus (FK506) in the rat
9. Effects of intestinal and hepatic metabolism on the bioavailability of tacrolimus in rats
10. The oral dosage form of FK-506
11. Pharmaceutical applications of cyclodextrins 1. Drug solubilization and stabilization
12. Cyclodextrin drug carrier system
13. Cyclodextrins: Their future in drug formulation and delivery
14. Cyclodextrin-enabling excipients: Their present and future use in pharmaceuticals
15. Highly soluble cyclodextrin derivatives: Chemistry, properties, and trends in development
16. Topical FK-506 prevents experimental corneal allograft rejection
17. FK-506 delays corneal graft rejection in a model of corneal xenotransplantation
18. Enhanced absorption of cyclosporin A by the complexation with dimethyl-β-cyclodextrin in bile duct-cannulated and noncannulated rats
19. Phase-solubility techniques
20. Kinetic analysis of molecular interconversion of immunosuppressant FK506 by high-performance liquid chromatography
21. Binding specificity between small organic solutes in aqueous solution: Classification of some solutes into two groups according to binding tendencies
22. Enhanced bioavailability of phenytoin by β-cyclodextrin complexation
23. Dissolution phenomena of organic medicinals involving simultaneous phase change
24. A highly sensitive method to assay FK-506 levels in plasma
25. Statistical moments in pharmacokinetics
26. Characterization of itraconazole/2-hydroxypropyl-β-cyclodextrin inclusion complex in aqueous propylene glycol solution
27. Cyclodextrins in drug carrier systems
28. Inclusion complexes of purine nucleotides with cyclodextrins. II. Investigation of inclusion complex geometry and cavity microenvironment
29. Cyclodextrin complexation of NSAIDS: Physicochemical characteristics
30. Circular dichroism study on inclusion complexes of some prostaglandins with α- and β-cyclodextrins
31. Conformational analysis of the cis- and transisomer of FK506 by NMR and molecular dynamics
32. Distribution and protein binding of FK506, a potent immunosuppressive macrolide lactone, in human blood and its uptake by erythrocytes
33. Pharmacokinetic study of FK506 in the rat
34. Pharmaceutics of FK-506, a novel immunosuppressant, after intravenous and oral administrations to rats
35. Pharmaceutical application of cyclodextrins. III. Toxicological issues and safety evaluation